hi lukelee
from james cornell market analyst I have known about it for a while it was brought up again in his last report issue 539
Most of Santalis early net cash flows were likely to have been earned from Galdermas royalties on benac
These earnouts if any will now be significantly lower
there is also a potential saving on the final earn out payment US$90million 20%of net cash flows inexcess of US$111*7 million over the first eight years
I have just relaid abit from the report but the point being made is the lost of sales of benzac is around 1 to 2 % of total sales revenues NOT A MAJOR Santalis is where the potential is & of coarse more royalties payments HELL I hope this helps ?
QIN Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
